生产(经济)
抗体
业务
生物
免疫学
经济
宏观经济学
出处
期刊:Cell engineering
日期:2011-01-01
被引量:5
标识
DOI:10.1007/978-94-007-1257-7
摘要
Engineered antibodies currently represent over 30% of biopharmaceuticals in clinical trials and their total worldwide sales continue to increase significantly. The importance of antibody applications
科研通智能强力驱动
Strongly Powered by AbleSci AI